Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

H. Segal, Neil; F. Logan, Theodore; Stephen Hodi, F.; McDermott, David; Melero, Ignacio; Hamid, Omid; Schmidt, Henrik; Robert, Caroline; Chiarion-Sileni, Vanna; A. Ascierto, Paolo; Maio, Michele; J. Urba, Walter; C. Gangadhar, Tara; Suryawanshi, Satyendra; Neely, Jaclyn; Jure-Kunkel, Maria; Krishnan, Suba; Kohrt, Holbrook; Sznol, Mario; Levy, Ronald

doi:10.1158/1078-0432.ccr-16-1272

Public

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Shared by NobleBlocks on Apr 13, 2017 • 12:00 AM UTC

Authors:

Neil H. Segal

Theodore F. Logan

F. Stephen Hodi

Abstract

Abstract Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing development in patients with advanced solid tu...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!